WINTON GROUP Ltd Decreases Stock Position in Vir Biotechnology, Inc. $VIR

WINTON GROUP Ltd lessened its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) by 58.3% in the 2nd quarter, Holdings Channel.com reports. The fund owned 153,491 shares of the company’s stock after selling 214,392 shares during the period. WINTON GROUP Ltd’s holdings in Vir Biotechnology were worth $1,564,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of VIR. Fiduciary Financial Advisors purchased a new stake in shares of Vir Biotechnology during the second quarter worth about $29,000. Raymond James Financial Inc. purchased a new position in shares of Vir Biotechnology in the 2nd quarter valued at approximately $35,000. UMB Bank n.a. boosted its stake in Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after purchasing an additional 6,597 shares in the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in Vir Biotechnology in the 4th quarter worth approximately $60,000. Finally, Daiwa Securities Group Inc. grew its position in Vir Biotechnology by 2,200.6% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock worth $62,000 after purchasing an additional 11,773 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Trading Up 0.4%

VIR opened at $10.62 on Friday. Vir Biotechnology, Inc. has a 12-month low of $4.75 and a 12-month high of $11.94. The firm has a 50 day moving average of $9.83 and a two-hundred day moving average of $9.55. The firm has a market capitalization of $1.80 billion, a PE ratio of -5.71 and a beta of 1.63.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.33 by $0.14. The business had revenue of $238.95 million for the quarter, compared to the consensus estimate of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The business’s revenue for the quarter was up 19582.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.80) EPS. As a group, analysts predict that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Analyst Ratings Changes

VIR has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a report on Monday, August 10th. Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Leerink Partners raised their target price on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Finally, Morgan Stanley set a $25.00 price target on Vir Biotechnology in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.57.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing therapies for serious infectious diseases and cancer. The company uses technologies involving antibodies, T cells, small interfering RNA and other immune-based approaches to discover and develop treatments designed to harness or enhance the body’s immune response.

Vir’s development programs have included therapies for hepatitis B, influenza, human immunodeficiency virus and other infectious diseases, as well as oncology applications.